Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

419
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

466
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
466
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

[Cognitive health of Moscow residents 55 years and older: Epidemiological data].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

Hypertension and Diabetes Cooperatively Drive HSP90 Activation, HSP70 Suppression, and Left Ventricular Interstitial Expansion: Relevance to Maladaptive Myocardial Remodeling.

Pathophysiology : the official journal of the International Society for Pathophysiology·2026
Same author

Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.

International journal of molecular sciences·2026
Same author

[Results of the program to preserve cognitive skills and psycho-emotional health in Moscow Longevity Centers].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

Ischaemia/reperfusion and permanent ischaemia differentially affect haemoglobin properties - Possible influence of oxidative stress and adaptation to acute hypoxia.

The FEBS journal·2026
Same author

Neuroinflammatory and Redox Responses in a Rat Model of NTG-Induced Migraine.

International journal of molecular sciences·2026

相关实验视频

Updated: Feb 28, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

治疗心力衰竭的基因疗法:对线粒体功能障碍的影响

Mikhail Blagonravov1,2, Anastasia Sklifasovskaya1, Ruslan Karpov2

  • 1Institute of Medicine, RUDN University, 6 Miklukho-Maklaya St, 117198 Moscow, Russia.

Biomedicines
|February 27, 2026
PubMed
概括

线粒体功能障碍通过损害能量生产导致心力衰竭 (HF). 使用腺关联病毒 (AAV) 载体的基因治疗提供了一种有前途的策略,通过输送必需基因来恢复心肌细胞功能.

关键词:
腺相关病毒 (AAVs) 的存在.基因治疗的基因疗法心脏衰竭是因为心脏衰竭.线粒体生物发生是线粒体生物发生.线粒体功能障碍 线粒体功能障碍矢量 矢量 是一个向量.

更多相关视频

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics
07:03

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics

Published on: August 23, 2024

1.6K
Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

9.2K

相关实验视频

Last Updated: Feb 28, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K
Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics
07:03

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics

Published on: August 23, 2024

1.6K
Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

9.2K

科学领域:

  • 心血管生物学 心血管生物学
  • 线粒体医学 线粒体医学
  • 基因治疗 基因治疗

背景情况:

  • 线粒体对心脏功能至关重要,它们的功能障碍是心力衰竭 (HF) 的标志.
  • HF涉及从脂肪酸氧化转向糖解,减少生物能储备.
  • 氧化应激和线粒体动力学损伤有助于HF的进展.

研究的目的:

  • 对高频率线粒体功能障碍的病理生理机制进行审查.
  • 探索基因疗法作为改善心肌细胞功能的一种策略.
  • 突出腺相关病毒 (AAV) 载体对于心脏基因传递的潜力.

主要方法:

  • 对高频率线粒体功能障碍的当前文献的综述.
  • 对基因治疗方法的分析针对心肌细胞.
  • 对心脏基因传递的AAV载体特征的评估.

主要成果:

  • 线粒体功能障碍,以氧化应激和改变的生物动力学为特征,显著影响HF.
  • 基因疗法提供了一种可行的方法来解决心肌细胞中的线粒体缺陷.
  • AAV 载体显示出有效地将基因传递到心脏细胞的前景.

结论:

  • 通过基因疗法准线粒体功能障碍是高频率的潜在治疗途径.
  • 通过AAV介导的基因传递为恢复心脏线粒体功能提供了一个有希望的策略.
  • 对心脏应用的AAV矢量优化进行进一步的研究是有必要的.